Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11745-11750. doi: 10.1073/pnas.1708420114. Epub 2017 Oct 16.

Favorable outcome of experimental islet xenotransplantation without immunosuppression in a nonhuman primate model of diabetes.

Author information

1
Department of Medicine III, University Hospital Carl Gustav Carus, Dresden D-01307, Germany; Barbara.Ludwig@uniklinikum-dresden.de andrew.schally@va.gov.
2
Paul Langerhans Institute Dresden of the Helmholtz Center Munich at The University Hospital Carl Gustav Carus and Faculty of Medicine of the TU Dresden, Dresden D-01307, Germany.
3
German Center for Diabetes Research (DZD e.V.), D-85764 Neuherberg, Germany.
4
Department of Surgery, University Hospital Carl Gustav Carus, Dresden D-01307, Germany.
5
Department of Medicine III, University Hospital Carl Gustav Carus, Dresden D-01307, Germany.
6
Pathology Unit, German Primate Center, Leibniz-Institute for Primate Research, Göttingen D-37077, Germany.
7
Beta-O2 Technologies, Petach-Tikva 49511, Israel.
8
Department of Pediatrics, University Hospital Carl Gustav Carus, Dresden D-01307, Germany.
9
Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139.
10
DFG-Center for Regenerative Therapies Dresden, Technische Universität Dresden D-01307, Germany.
11
Max Planck Institute of Molecular Cell Biology and Genetics, Dresden D-01307, Germany.
12
Department of Pathology, Miller School of Medicine, University of Miami, Miami, FL 33136; Barbara.Ludwig@uniklinikum-dresden.de andrew.schally@va.gov.
13
Department of Medicine, Division of Hematology-Oncology, Miller School of Medicine, University of Miami, Miami, FL 33136.
14
Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, FL 33136.
15
Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, FL 33125.
16
Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL 33136.
17
Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136.
18
Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London SE1 1UL, United Kingdom.

Abstract

Transplantation of pancreatic islets for treating type 1 diabetes is restricted to patients with critical metabolic lability resulting from the need for immunosuppression and the shortage of donor organs. To overcome these barriers, we developed a strategy to macroencapsulate islets from different sources that allow their survival and function without immunosuppression. Here we report successful and safe transplantation of porcine islets with a bioartificial pancreas device in diabetic primates without any immune suppression. This strategy should lead to pioneering clinical trials with xenotransplantation for treatment of diabetes and, thereby, represents a previously unidentified approach to efficient cell replacement for a broad spectrum of endocrine disorders and other organ dysfunctions.

KEYWORDS:

beta-cell replacement; diabetes; immune barrier; porcine islets

PMID:
29078330
PMCID:
PMC5676906
DOI:
10.1073/pnas.1708420114
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center